OncoMed Announces Appointment of John Lewicki, PhD, as President, Chief Executive Officer and a member of the Board of Directors

Via: OncoMed

REDWOOD CITY, Calif., March 19, 2018 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics, today announced the appointment of Dr. John Lewicki as President and Chief Executive Officer of OncoMed, effective immediately. Dr. Lewicki was also appointed to the company's Board of Directors. 

"John has been a key member of the OncoMed leadership team since the formation of the company, and he has guided our science to the discovery and development of all of our therapeutic candidates," said Perry Karsen, Executive Chairman of OncoMed's Board of Directors. "The OncoMed Board of Directors and I are fully confident that John's leadership as President and Chief Executive Officer will help ensure the company maximizes the value of our therapeutic candidates for cancer patients and our shareholders.  We look forward to working closely with John and the entire OncoMed team to have a positive impact on cancer patients."

Read More: ​http://www.oncomed.com/invest/releasedetail.cfm?ReleaseID=1061305